November 1st, 2023

inSoma Raises $2.5M in Seed Round

inSoma today announced it has raised $2.5 million in 2023 as part of a seed round. The raise builds on an initial pre-seed round raised in 2020, as well as the continued grant funding that inSoma has received from the NIH and NSF, and deepens the financial foundation from which to advance the development of a portfolio of injectable materials designed to mimic human tissue that can be used to rebuild a person’s tissue more safely and accurately, without the need for synthetic implants or fillers.

September 1st, 2023

NSF Awards inSoma $1M Grant to Evaluate Fractomer’s Potential in Facial Fat Grafting

inSoma Bio has been awarded a highly competitive grant through the National Science Foundation (NSF) to explore the potential of Fractomer™️ in an additional soft tissue reconstruction application, facial fat grafting. This follow-on commercialization grant from the NSF further validates the broad potential of inSoma’s technology.

March 31st, 2023

NIH Awards inSoma $250K to Evaluate Fractomer’s Potential to Improve Skin Grafting

The National Institutes of Health (NIH) has awarded inSoma a $250,000 grant to explore an exciting early phase potential additional regenerative reconstruction application for inSoma’s proprietary recombinant elastin-based biomaterial Fractomer™️ – as an effective, lower-cost skin grafting support matrix for the treatment of severe burn wounds.

Read whole article